CCO Annual Update
Hepatitis Annual Update 2009
HBV Infection: Deciding Who and When to Treat |
Module 1 of 5 |
|
Program Director: Marion G. Peters, MD, FRACP
|
|
Anna S. F. Lok, MD, discusses factors to consider when evaluating patients with chronic hepatitis B infection for initiating treatment.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Identify 2 patient and/or clinical factors that serve as indications for HBV treatment deferral
- Discuss patient and/or clinical factors that serve as indications for treatment initiation in HBV-infected patients
- Compare and contrast finite vs long-term HBV treatment strategies
Abstract
|
Benefits and Risks of HBV Therapy |
Module 2 of 5 |
|
Program Director: Marion G. Peters, MD, FRACP
- Geoffrey M. Dusheiko, MD, FCP(SA), FRCP
|
|
|
Geoffrey M. Dusheiko, MD, FCP(SA), FRCP, reviews the benefits and risks of hepatitis B management using currently available therapeutic agents.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe the available treatment options for first-line therapy of HBV
- Compare the advantages and disadvantages of current HBV treatment options
- Describe the clinical consequences of HBV resistance, focusing on prevention of resistance
- Recount the factors that determine whether to continue or change HBV therapy
Abstract
|
Update on Investigational HCV Agents |
Module 3 of 5 |
|
Program Director: David L. Thomas, MD, MPH
- Jean-Michel Pawlotsky, MD, PhD
|
|
|
Jean-Michel Pawlotsky, MD, PhD, discusses how insights into the virology of HCV have unraveled several targets for potential novel therapeutics.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe the molecular virology of hepatitis C virus (HCV) and targets of pharmacologic intervention
- Recount the current understanding of resistance mutations with new HCV therapies
- Discuss recent efficacy and safety data from phase II or later studies of investigational agents for HCV (including targeted therapies, novel interferons, and potential interferon enhancers such as nitazoxanide)
- Compare the potential impact that investigational agents may have on the management of patients with HCV (including the role of pegylated interferon and ribavirin)
Abstract
|
Mechanisms of Response and Nonresponse to HCV Treatment |
Module 4 of 5 |
|
Program Director: David L. Thomas, MD, MPH
|
|
Raymond T. Chung, MD, reviews the mechanisms of response and nonresponse in HCV treatment, including fixed and modifiable factors.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss the current understanding of the mechanisms of action of interferon and ribavirin in chronic HCV infection, including pegylated interferon, consensus interferon, and novel interferons (excluding standard interferon)
- Identify factors associated with response and nonresponse to peginterferon and ribavirin
- Using knowledge about mechanisms of response, apply a management strategy that might improve response in a difficult-to-treat patient
- Identify 2 key time points and markers for assessing and evaluating response to HCV treatment
Abstract
|
Update in the Diagnosis and Management of Decompensated Cirrhosis |
Module 5 of 5 |
|
Program Director: David L. Thomas, MD, MPH
|
|
Timothy Morgan, MD, reviews current treatment reccomendations for the management of advanced liver disease and its complications in the context of recent clinical trial data.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe new findings on the diagnosis and treatment of hepatic encephalopathy
- Review optimal treatment and diagnostic approaches for variceal bleeding
- Compare and contrast the current and emerging options for treating ascites and hepatorenal syndrome
- Recount data supporting prophylactic therapy for the prevention of spontaneous bacterial peritonitis in patients with cirrhosis and ascites
- Apply the most effective screening and diagnostic procedures when evaluating patients for hepatocellular carcinoma
Abstract
|
CCO Slideset
Hepatitis Annual Update 2009
 |
|
Review the latest data on HBV and HCV management, as well as the diagnosis and management of decompensated cirrhosis.
Format: Microsoft PowerPoint (.ppt) |
File size: 2.04 MB
| Date posted: 8/7/2009
|
Disclaimer:
The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.
|
Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.
Contact Info
Educational grants provided by:
Educational grants support only the CME/CE-certified components of this program.
|